MetaCap

Inhibikase Therapeutics (IKT) vs Lineage Cell Therapeutics (LCTX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Inhibikase Therapeutics (IKT) has outperformed Lineage Cell Therapeutics (LCTX) over the past year, losing 11.4% versus a loss of 55.6%. Over five years, LCTX leads with a -61.2% price change compared with -89.3% for IKT. Lineage Cell Therapeutics is the larger company by market cap ($195.3 million vs $185.2 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

IKT-11.41%LCTX-55.64%
+75%+7%-62%
Nov 21, 20251 yearNov 20, 2026
IKT-88.42%LCTX-66.29%
+23%-38%-98%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

IKT versus LCTX key metrics
MetricIKTLCTX
Share price$1.32$0.7719
Market cap$185.16M$195.26M
1-day change+1.54%-5.87%
YTD return-35.61%-53.78%
1-year return-11.41%-55.64%
5-year return-89.32%-61.21%
EPS (TTM)$-0.40$-0.09
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$14.56M
Revenue growth (YoY)—+53.24%
Net income (latest FY)$-48.26M$-63.53M
Operating margin—-251.57%
Net margin—-436.47%
52-week high$2.61$1.99
52-week low$1.28$0.77
Distance from 52-week high-49.43%-61.21%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+320.45%+612.53%
Average volume584.27K1.64M
Shares outstanding140.27M252.95M
Employees3572
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • IKT has outperformed LCTX by 44.2 percentage points over the past year.

About Inhibikase Therapeutics

IKT stock →

Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 35 employees

About Lineage Cell Therapeutics

LCTX stock →

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; and OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 72 employees

IKT vs LCTX FAQ

Which is bigger, Inhibikase Therapeutics or Lineage Cell Therapeutics?

Lineage Cell Therapeutics (LCTX) is larger, with a market capitalization of $195.26M compared with $185.16M for Inhibikase Therapeutics (IKT).

Which stock has performed better over the past year, IKT or LCTX?

IKT returned -11.41% over the past 12 months, compared with -55.64% for LCTX (price return, excluding dividends). Past performance does not predict future results.

Are Inhibikase Therapeutics and Lineage Cell Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons